aromasil has been researched along with Cells, Neoplasm Circulating in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Apostolaki, S; Georgoulia, N; Georgoulias, V; Hatzidaki, D; Kallergi, G; Koinis, F; Kotsakis, A; Nikolaou, C; Politaki, E; Spiliotaki, M; Tsoukalas, N; Xenidis, N | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Beckmann, MW; Fasching, PA; Fehm, T; Friedl, TWP; Gade, J; Janni, W; Lichtenegger, W; Lorenz, R; Mahner, S; Müller, V; Pantel, K; Polasik, A; Rack, B; Rezai, M; Schindlbeck, C; Schneeweiss, A; Schochter, F; Soeling, U; Tesch, H; Trapp, E; Tzschaschel, M | 1 |
| Bondarenko, I; Brain, E; Campone, M; De Porre, P; Gormley, M; Graas, MP; Griffin, T; Hayes, D; Ivanova, O; Johnston, SR; Kheoh, T; Li, W; Martin, J; Neven, P; O'Shaughnessy, J; Ricci, D; Schaffer, M; Stenina, M; Yu, M; Zbarskaya, I; Zelinsky, K | 1 |
2 trial(s) available for aromasil and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study.
Topics: Androstadienes; Breast Neoplasms; Female; Humans; Neoplastic Cells, Circulating; Postmenopause; Tamoxifen | 2018 |
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Middle Aged; Neoplastic Cells, Circulating; Postmenopause; Receptors, Androgen; Receptors, Estrogen; Steroid 17-alpha-Hydroxylase | 2016 |
1 other study(ies) available for aromasil and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; Receptor, ErbB-2; Salvage Therapy; Treatment Outcome | 2021 |